15353-j-veluchamy

156 | Chapter 6 References 1. ShaimH, Yvon E. Cordblood: a promising sourceof allogeneic natural killer cells for immunotherapy. Cytotherapy (2015) 17 (1):1-2. doi: http://dx.doi.org/10.1016/j.jcyt.2014.12.001. 2. Spanholtz J, Tordoir M, Eissens D, Preijers F, Meer A, Joosten I, et al. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS One (2010) 5 . doi: 10.1371/journal.pone.0009221. 3. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T, et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One (2011) 6 (6):e20740. Epub 2011/06/24. doi: 10.1371/journal.pone.0020740. PubMed PMID: 21698239; PubMed Central PMCID: PMCPmc3116834. 4. Cany J, van der Waart AB, Tordoir M, Franssen GM, Hangalapura BN, de Vries J, et al. Natural Killer Cells Generated from Cord Blood Hematopoietic Progenitor Cells Efficiently Target Bone Marrow-Residing Human Leukemia Cells in NOD/SCID/IL2Rg<sup>null</sup> Mice. PLoS ONE (2013) 8 (6):e64384. doi: 10.1371/journal.pone.0064384. 5. Lehmann D, Spanholtz J, Osl M, Tordoir M, Lipnik K, Bilban M, et al. Ex vivo generated natural killer cells acquire typical natural killer receptors and display a cytotoxic gene expression profile similar to peripheral blood natural killer cells. Stem cells and development (2012) 21 (16):2926- 38. Epub 2012/05/11. doi: 10.1089/scd.2011.0659. PubMed PMID: 22571679; PubMed Central PMCID: PMCPmc3475144. 6. Veluchamy JP, Heeren AM, Spanholtz J, van Eendenburg JD, Heideman DA, Kenter GG, et al. High- efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status. Cancer immunology, immunotherapy : CII (2017) 66 (1):51-61. Epub 2016/10/27. doi: 10.1007/s00262-016-1919-1. PubMed PMID: 27783105. 7. Veluchamy JP, Lopez-Lastra S, Spanholtz J, Bohme F, Kok N, Heideman DAM, et al. In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer. Frontiers in Immunology (2017) 8 (87). doi: 10.3389/fimmu.2017.00087. 8. Rosenberg SA. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J Sci Am (2000) 6 Suppl 1 :S2-7. Epub 2000/02/24. PubMed PMID: 10685650. 9. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med (1987) 316 (15):898-905. Epub 1987/04/09. doi: 10.1056/nejm198704093161502. PubMed PMID: 3493433. 10. Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol (2015) 33 (1):74-82. Epub 2014/11/19. doi: 10.1200/jco.2014.57.3329. PubMed PMID: 25403209; PubMed Central PMCID: PMCPMC4268254.